LYMPHOBLASTIC LYMPHOMA IN ADULTS
LYMPHOBLASTIC LYMPHOMA IN ADULTS
复制标题
DOI：
10.1200/jco.1986.4.1.57
复制
发表时间：
1986-01-01
影响因子：
45.3
通讯作者：
CLARKSON, BD
中科院分区：
文献类型：
--
作者：
SLATER, DE;MERTELSMANN, R;CLARKSON, BD
本文回顾了自1971年以来采用5种不同方案治疗急性淋巴细胞白血病（ALL）的51例淋巴母细胞淋巴瘤（LBL）。将患者分为白血病组和非白血病组，比较其临床和实验室指标。所有接受L10/17方案治疗的白血病和非白血病LBL患者的预计5年生存率均为45%。对治疗的反应与111例ALL患者进行了比较，结果几乎相同。不良预后因素是年龄超过30岁、WBC > 50，000/μ L、未能达到完全反应（CR）和诱导期间的晚期CR。白血病在介绍，T细胞表面标志物，并存在纵隔肿块没有不利影响生存。使用强化化疗方案已被证明是治疗LBL的一个重大进展。
Fifty-one patients with lymphoblastic lymphoma (LBL) treated with one of five successive intensive chemotherapy protocols for acute lymphoblastic leukemia (ALL) since 1971 were reviewed. The patients were divided into leukemic and nonleukemic groups, and their clinical and laboratory parameters compared. The projected 5-year survival rate for all patients treated with the L10/17 protocols was 45% for both leukemic and nonleukemic LBL. The response to treatment was compared with that of 111 patients with ALL and was nearly identical. Poor prognostic factors were age beyond 30, WBC > 50,000/.mu.L, failure to achieve a complete response (CR), and a late CR during induction. Leukemia at presentation, T cell surface markers, and the presence of a mediastinal mass did not adversely affect survival. The use of intensive chemotherapy protocols has proven to be a significant advance in the treatment of LBL.